JAK-IN-29
JAK-IN-29 (compound 3) is a potent JAK inhibitor[1].
Product Specifications
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/jak-in-29.html
Solubility
10 mM in DMSO
Smiles
O=C(N)C1=CN=C(NC2=NC(O)=CC=C2)C=C1NC3=CC=CC=C3Cl
Molecular Formula
C17H14ClN5O2
Molecular Weight
355.78
References & Citations
[1]Gebhard Thoma, et al. Novel Concept for Super-Soft Topical Drugs: Deactivation by an Enzyme-Induced Switch into an Inactive Conformation. ACS Med Chem Lett. 2023 May 30;14 (6) :841-845.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC401976-500 1x 500 µL
CD27 (Tumor Necrosis Factor Receptor Superfamily 7) (rLPFS2/1611), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details ![Ethyl (1R,5R,6R)-7-acetyl-5-(pentan-3-yloxy)-7-azabicyclo[4.1.0]hept-3-ene-3-carboxylate](https://cdn.genprice.uk/products/572/1272668742252/imageurl/trc-e295380-2.5mg.webp)
TRC-E295380-2.5MG 2.5 mg
Ethyl (1R,5R,6R)-7-acetyl-5-(pentan-3-yloxy)-7-azabicyclo[4.1.0]hept-3-ene-3-carboxylate
Sign In for Pricing
View Details 
BNC941791-100 1x 100 µL
SOX2 (Transcription Factor) (SOX2/1791), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
